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ABSTRACT
Interaction of Ebola virus matrix protein VP40 with RNA is crucial in the early infection stage to facilitate the 
transcription of the viral gene. Thus, VP40 is a promising target to inhibit the Ebola virus from spreading. This study 
aims to identify and optimize ligands that can potentially block the VP40-RNA binding site. A total of 42 compounds 
from previously studied ligands from the literature were simulated against the RNA binding site using Autodock Vina. 
The top ten ligands were used as templates for similarity search in ZINC database followed by structured-based virtual 
screening. Then, the ADME properties of the top compounds were predicted computationally using SwissADME server. 
Our results showed that Q-96 (ZINC ID: 1338855) is the best docked compound with binding free energy of -7.5 kcal/
mol. The compound also has satisfactory ADME properties prediction with good lipophilicity value, moderate water 
solubility and high gastrointestinal absorption. Besides, this ligand does not violate any drug likeness rules as well as 
no PAINS and Brenk alerts, indicate it has the properties as a drug. Thus, it is worth to carry out further investigations 
on this structure more in silico as well as in vitro and in vivo levels towards finding the treatment for Ebola virus 
disease.
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ABSTRAK
Interaksi matriks virus Ebola VP40 dengan RNA adalah penting dalam peringkat jangkitan awal untuk memudahkan 
transkripsi gen virus. Oleh itu, VP40 adalah sasaran yang sesuai bagi menghalang virus Ebola daripada terus merebak. 
Kajian ini bertujuan untuk mengenal pasti dan mengoptimumkan ligan yang berpotensi menghalang tapak pengikat 
VP40-RNA. Sejumlah 42 sebatian daripada kajian terdahulu telah disimulasi di tapak pengikat RNA menggunakan 
Autodock Vina. Sepuluh ligan terbaik telah dipilih sebagai templat pencarian persamaan dalam pangkalan data ZINC 
diikuti oleh penyaringan maya berasaskan struktur. Ciri-ciri ADME sebatian telah diramalkan secara komputasi 
menggunakan pelayan SwissADME. Keputusan kajian kami menunjukkan bahawa Q-96 (ZINC ID: 1338855) adalah 
sebatian terbaik dengan tenaga bebas pengikat -7.5 kcal/mol. Sebatian ini juga menunjukkan sifat ADME yang 
memuaskan dengan nilai kelipofilikan yang baik, kelarutan air secara sederhana dan penyerapan gastrousus yang 
tinggi. Selain itu, ligan ini tidak melanggar sebarang hukum persamaan drug juga tidak memberi sebarang amaran 
PAINS dan Brenk, menjustifikasikan ia mempunyai ciri-ciri sebagai drug. Oleh itu, adalah wajar untuk menjalankan 
kajian lanjutan yang lebih dalam mengenai struktur ini secara in silico, in vitro dan in vivo ke arah pencarian rawatan 
terhadap penyakit virus Ebola.
Kata kunci: ADME; cantuman molekul; protein matriks VP40; virus Ebola
INTRODUCTION
Ebola Virus (EBOV) is a lipid-enveloped filamentous virus 
that leads to the Ebola virus disease (EVD) which is 
formerly known as Ebola hemorrhagic fever, a severe 
disease that was first appeared in 1976 in two concurrent 
outbreaks; one was in Nzara, South Sudan and the other 
one was in Yambuku, Democratic Republic of Congo. The 
virus was transmitted to people from wild animals and then 
spread to the human population through human-to-human 
transmission with a fatality rate up to 90% (Feldmann & 
Geisbert 2011). It has been suggested that the virus resides 
in fruit bats of Pteropodidae family as its natural host 
(WHO | Ebola virus disease 2017). The 2014-2016 Ebola 
outbreak in West Africa was known as the largest and most 
complex Ebola outbreak. During that time, EVD had spread 
between countries including Liberia, Nigeria and the USA 
(WHO | Ebola virus disease 2017). In August 2018, an 
EVD outbreak was declared by the Ministry of Health of 
the Democratic Republic of the Congo that took place in 
North Kivu Province. By June 2019, more than 2000 cases 
were confirmed with 1506 deaths (WHO | Ebola situation 
reports: Democratic Republic of the Congo 2019).
EBOV harbours a negative-sense single-stranded RNA 
(ssRNA) genome with the length of 19 kb that encodes 
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seven proteins namely nucleoprotein, VP30, VP35, 
L-polymerase (L) protein, VP24, transmembrane 
glycoprotein (GP) and VP40. Each of these encoded 
proteins plays different functions throughout the Ebola 
virus life cycle. Transmembrane GP is the only protein on 
the surface of the virion and accounted for the entry of the 
virion into the host cells (Martin et al. 2016). Meanwhile, 
L protein which is an RNA-dependent RNA polymerase 
(RdRp) involves in viral genome transcription and 
translation by forming the RdRp complex together with 
VP30 (Martin et al. 2017). VP24 and VP35 are involved 
in inhibition of interferon signalling to avoid host immune 
response while VP40, the viral matrix protein is responsible 
for the viral assembly and budding as well as virus structure 
and stability (Booth et al. 2013; Olejnik et al. 2011). VP30 
and VP40 were also found to be suppressors of RNA 
silencing beside VP35 (Fabozzi et al. 2011).
Among all of Ebola’s protein, the matrix protein VP40 
is considered as a promising drug target as it can induce 
virus-like particles (VLPs) formation even when expressed 
alone (Jasenosky et al. 2001). Besides, each different 
conformation of this protein reflects its different role 
throughout the Ebola life cycle. The monomeric form of 
VP40 serves as the building block for higher configuration 
of the VP40 (Adu-Gyamfi et al. 2012). Meanwhile, VP40 
dimer and hexamer were shown to be associated with 
membrane interaction especially negatively charged lipid-
like phosphatidylserine (PS) and phosphatidylinositol 
4,5-bisphosphate (PIP2), through its cationic patch in the 
C-terminal domain (Adu-Gyamfi et al. 2015; Del Vecchio 
et al. 2018; Gc et al. 2017; Johnson et al. 2016). VP40 also 
exist in octameric ring form and associates with the RNA 
binding activity through its N-terminal domain (Gomis-
Rüth et al. 2003; Ruigrok et al. 2000)
VP40-RNA binding activity plays an important role 
during its life cycle. Two amino acid residues namely 
Arg134 and Phe125 were shown to be the key residues 
involved in the RNA binding activity (Hoenen et al. 2005) 
(Figure 1). The mutation on these residues affects the 
RNA-binding process where mutation of Phe125 into Ala 
decreased RNA binding activity, meanwhile mutation of 
Arg134 to Ala abolished the RNA binding activity as well 
as the formation of VP40 octamer (Hoenen et al. 2005). 
This RNA binding activity is crucial in viral transcription 
regulation as VP40 in ring form can recapitulate the 
transcription control function thus plays a significant role 
in Ebola life cycle especially in the early stage of infection 
(Bornholdt et al. 2013). Therefore, this RNA binding site 
serves as a potential drug target to interrupt the Ebola life 
cycle.
To date, no FDA-licensed drug is available to solve 
this problem and most of the potential drugs to treat the 
disease are yet to be used in human clinical trials (Yuan 
2015). From the 2014-2016 outbreak, the calling for further 
research on understanding Ebola life cycle is more urgent 
than before. Even though the outbreak has mainly occurred 
in West Africa, current mobility in term of transportation 
might spread the disease further from its origin (Gonzalez 
et al. 2018). The situation can be worsened in the future 
due to the increase in human population which eases the 
transmission of disease through human to human 
transmission. Therefore, this study focuses on developing 
a potential drug for EVD by targeting the RNA binding 
site. Several computational studies have been carried out 
to find the potential VP40 inhibitors at the RNA binding 
site. For instance, a compound with ID ASN03576800 
from Asinex database was identified by Tamilvanan and 
Hopper (2013) as a potential lead compound to inhibit 
VP40-RNA binding activity. Meanwhile, six potential 
compounds were identified by Raj and Varadwaj (2016) 
by screening flavonoid compounds from Timtec library. 
On the other hand, two compounds namely emodin-8-beta-
D-glucoside and tonkinochromane_G from TCMD were 
reported by Karthick et al. (2016) as potential VP40-RNA 
inhibitors. Recently, several candidates of natural herbal 
ligands namely Mahanine, Mahanimbine and Gumnosine 
were also found to have favourable interaction with VP40 
(Setlur et al. 2017). 
In total, 42 compounds have been reported to 
potentially block the VP40-RNA binding activity. 
However, all these previous studies only focused on in 
silico and none proceeded any further either in vivo and 
FIGURE 1. Truncated VP40 monomer structure with its important residues (Arg134 and Phe125) that involve in binding of ssRNA
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in vitro. Besides, all these studies mainly relied on 
screening compounds from various databases without 
any specific scaffold to suit the RNA binding site. Thus, 
this study was conducted to find and optimize the 
potential new ligands based on previously studied 
compounds for better inhibition at the RNA binding site. 
By considering all 42 previous studied compounds as 
starting template, both virtual screening method; ligand-
based and structure-based through similarity search of 
compounds of similar scaffold in ZINC database were 
utilized in this study. The results presented in this study 
provide insights into the potential compounds that can 
block VP40-RNA binding activity.
METHODS
PROTEIN PREPARATION
The crystal structure of VP40 model was taken from 
Protein Data Bank (PDB) [PDB Entry: 1H2C]. The protein 
was cleaned by removing all other molecules in the 
complex including water atoms in the PDB file. The RNA 
binding site for docking simulation was predicted using 
COACH (Yang et al. 2013a, 2013b) accounting the 
important residues for RNA-binding activity, Arg134 and 
Phe125. Six residues were predicted to be in the RNA 
binding site namely Thr123, Phe125, Gly126, Lys127, 
Arg134, and Tyr171.
LIGANDS PREPARATION AND MOLECULAR DOCKING OF 
PREVIOUSLY STUDIED LIGANDS
A total of 42 ligands that were previously studied against 
RNA binding site of the VP40 protein have been identified 
from literatures (Abazari et al. 2015; Karthick et al. 2016; 
M Alam El-Din et al. 2016; Mirza & Ikram 2016; Raj & 
Varadwaj 2016; Setlur et al. 2017; Shah et al. 2015; 
Tamilvanan & Hopper 2013). The compounds were 
labelled as L-1 till L-42. Since the compounds were 
previously docked using different software, we performed 
a set of docking simulations using a single software, 
AutoDock Vina version 1.1.2 (Trott & Olson 2009). This 
software was chosen in this study as it provides faster 
calculation to pose the compound at the binding site as 
well as predicts the compound’s binding mode more 
accurately (Trott & Olson 2009). Furthermore, a 
comparison between several docking tools showed that 
AutoDock Vina has quite similar performance as Glide 6.6 
and DOCK 6.5 but perform better than AutoDock 4 
(Castro-Alvarez et al. 2017). Polar hydrogens were added 
to both protein and ligands while non-polar hydrogens 
were merged with the structure. Then, Kollman charges 
were added to the protein and ligands. The grid box was 
set to be 14.25 × 20.25 × 21 with 1 Å distance spacing. 
The grid centre was set to be 1.641, 14.662 and 28.551 for 
x, y and z value, respectively. The maximum number of 
binding modes was set at 10 while the default exhaustiveness 
value was used during the simulation. Top ten ligands with 
the lowest binding energy were selected to serve as a 
template for ligand-based virtual screening in the next step. 
LIGAND-BASED VIRTUAL SCREENING
Ligand-based virtual screening was carried out to screen 
compounds from ZINC database that have similar scaffold 
to the templates. The virtual screening was carried out 
using USRCAT (Schreyer & Blundell 2012), an extension 
of USR at the USR-VS server (Li et al. 2016). The top ten 
ligands with preferred orientation and low binding energy 
at the RNA binding site from the first stage molecular 
docking was used as a template for the screening. Only 20 
similar structures from the screening, ranked according to 
the USRCAT score for each template were taken for the 
next screening step resulting in a total of 200 new ligands. 
The new ligands were labelled as Q-1 till Q-200.
MOLECULAR DOCKING OF NEW LIGANDS FROM 
SIMILARITY SEARCH
All 200 ligands were docked at the predicted RNA binding 
site using Autodock vina version 1.1.2. (Trott & Olson 
2009). The compounds were ranked according to the order 
of binding energy, from the lowest to the highest as well 
as accounting the orientation of the ligand at the RNA 
binding site. Top 10 compounds that have better binding 
energy than the previously studied ligands were selected 
for the next step.
LIGANDS ADME ANALYSIS
The ADME properties of the top 10 compounds from 
structure-based virtual screening were predicted using 
SwissADME (Daina et al. 2017). The bioavailability radar 
to assess the drug-likeness of a compound based on six 
parameters; lipophilicity, size, polarity, solubility, 
flexibility and saturation was considered to select the best 
ligand. The compounds also being assessed for Lipinski’s 
(Lipinski et al. 1997), Ghose’s (Ghose et al. 1999), Veber’s 
(Veber et al. 2002), Egan’s (Egan et al. 2000) and Muegge’s 
(Muegge et al. 2001) rules violation.
RESULTS AND DISCUSSION
MOLECULAR DOCKING OF PREVIOUSLY STUDIED 
LIGANDS
All 42 reported compounds in the literature that were 
previously investigated and targeted against VP40-RNA 
binding activity (Table 1) were docked again at the binding 
site using AutoDock Vina. Table 1 shows the top 10 out of 
42 compounds according to its binding energy as well as 
residues involved in the binding interactions. All ten 
compounds displayed close contact with Phe125 and 
Arg134, the two important residues in mediating the VP40-
RNA binding activity (Gomis-Rüth et al. 2003; Hoenen et 
al. 2005). L-38 has the best binding energy of -6.7 kcal/
mol and formed three H-bonds with residues Thr123, 
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His124 and Gly126 followed by L-21 (-6.5 kcal/mol) 
which also formed three H-bonds with the protein, one 
with Arg134 and two with Phe172. The ten compounds 
were then used as templates for ligand-based virtual 
screening in USR-CAT server to find compounds with 
similar scaffold as described in Methods. 200 new 
compounds were obtained based on the similarity score 
from virtual screening process and proceed for the next 
docking stage. 
MOLECULAR DOCKING OF NEW LIGANDS FROM 
SIMILARITY SEARCH
A structure-based virtual screening of 200 compounds 
against RNA binding site was carried out and the ligands 
were ranked based on binding energy and preferred 
orientation at the binding site. From the simulations, 10 
compounds were identified to give lower binding energy 
than the previous docking stage (-6.7 kcal/mol) and closely 
interacted with the RNA binding residues (Table 2). Q-96 
has the lowest binding energy of -7.5 kcal/mol and formed 
one H-bond with Arg134. Q-83 has the most H-bonds 
formed with the RNA binding residues namely Gly126 
and Arg134. We observed that all ten compounds interacted 
with Phe125 and Arg134 and with three other residues 
namely His124, Gln170 and Tyr171.
From the docking results, we found that the top 10 
compounds are the results of ligand-based virtual 
screening from L-38, the top ligands from the first 
molecular docking stage. These 10 compounds can further 
be divided into two similar scaffold groups where Q-94, 
Q-97, Q-98 and Q-99 are grouped into a piperidine-based 
scaffold group containing benzene, oxadiazole, piperidine 
and carboxamide chain while Q-96, Q-93, Q-82, Q-83, 
Q-88 and Q-100 are grouped into pyridine-based scaffold 
that contains two benzene rings (one as benzamide and 
another as phenyl), triazole and pyridine except for Q-83 
which has an oxadiazole ring instead of triazole. L-38 
also has similar scaffold as pyridine-based group with S 
atom acting as the bridge to connect the two rings from 
each side into a single structure but having different 
chemical constituents at the ring of the structure (Figure 
2). In general, all ten compounds have benzene in their 
structure as benzene is the most common ring listed in 
drug database followed by pyridine and piperidine (Taylor 
et al. 2014).
LIGANDS ADME ANALYSIS
The ADME properties of the potential ligands were 
computationally determined using SwissADME. From the 
result generated in SwissADME server, we found that all 
ten compounds did not violate the Lipinski’s rule of five 
indicated that they have good drug-likeness properties. 
Also, we looked for any drug-likeness violations according 
to the other modified rules (Table 3) and found that Q-83 
violates one Egan’s rules by having TPSA value greater 
than 131.6 while Q-88 does not meet two Ghose’s rule 
with a molecular weight exceeding 480 g/mol and molar 
refractivity above 130. Meanwhile, Q-99 violates one 
Ghose’s rule. All ligands gave an average bioavailability 
score of 0.55.
Even though some of the ligands violated few drug-
likeness rules, all the compounds gave good lipophilicity 
properties with the consensus Log P value between ~2.2 
and 3.4 (Table 4). According to Lipinski et al. (1997), log 
P should not exceed 5, as a desirable lipophilicity range 
for a compound to reach Phase II clinical trials. It is also 
noted that compounds with log P < 4 and molecular weight 
below 400 g/mol have better ADMET properties (Gleeson 
2008). Furthermore, compounds with high lipophilicity (> 
5) usually lead to rapid metabolic turnover (Waterbeemd 
TABLE 1. Top docking result of previously reported compounds. Bolded residues are important residues in RNA binding activity
Ligands Binding energy (kcal/mol) No of H-bonds H-bond residues Interacting residues
L-38 -6.7 3 Thr123, His124, Gly126 Thr123, His124, Phe125, Gly126, Lys127, 
Ala128, Arg134, Gln170, Tyr171
L-21 -6.5 3 Arg134, Phe172(2) Thr123, His124, Phe125, Arg134, Tyr171, 
Phe172, Thr173
L-6 -6.4 - - Phe125, Arg134, Tyr171, Phe172, Thr173
L-1 -6.3 1 Arg134 Phe125, Gly126, Arg134, Tyr171
L-2 -6.3 1 Arg134 Thr123, Phe125, Arg134, Gln170, Tyr171
L-3 -6.3 1 Arg134 Thr123, His124, Phe125, Gly126, Ala128, 
Arg134, Gln170, Tyr171
L-32 -6.3 3 Gly126, Ala128, Arg134 Thr123, His124, Phe125, Gly126, Lys127, 
Ala128, Arg134, Gln170, Tyr171
L-4 -6.2 2 Arg134, Thr173 Thr123, His124, Phe125, Arg134, Tyr171, 
Thr173
L-10 -6.2 1 Arg134 Thr123, Phe125, Gly126, Arg134, Gln170, 
Tyr171
L-22 -6.2 2 His124, Arg134 His124, Phe125, Gly126, Arg134, Tyr171
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TABLE 2. Top compounds from virtual screening and molecular docking process. Bolded residues are important residues in RNA 
binding activity
Ligand ZINC ID Binding energy (kcal/mol) No of H-bonds H-bond residues Interacting residues
Q-96 1338855 -7.5 1 Arg134 Thr123, His124, Phe125, Gly126, 
Ala128, Arg134, Gln170, Tyr171
Q-82 1338833 -7.4 - - Thr123, His124, Phe125, Ala128, 
Pro131, Arg134, Gln170, Tyr171
Q-97 40958549 -7.3 2 Gln170, Tyr171 Thr123, His124, Phe125, Gly126, 
Ala128, Arg134, Gln170, Tyr171
Q-83 59213111 -7.2 3 Gly126, Arg134 
(2)
Thr123, His124, Phe125, Gly126, 
Arg134, Gln170, Tyr171
Q-93 1338837 -7.2 1 Arg134 Thr123, His124, Phe125, Gly126, 
Ala128, Arg134, Gln170, Tyr171
Q-88 1342431 -7.1 - - Thr123, His124, Phe125, Gly126, 
Ala128, Pro131, Arg134, Gln170, 
Tyr171
Q-94 40930748 -6.9 1 His124 Thr123, His124, Phe125, Gly126, 
Ala128, Arg134, Gln170, Tyr171
Q-98 41279804 -6.9 2 Arg134, Tyr171 His124, Phe125, Gly126, Arg134, 
Gln170, Tyr171
Q-99 41279972 -6.9 1 Arg134 Thr123, His124, Phe125, Gly126, 
Ala128, Arg134, Gln170, Tyr171
Q-100 1342435 -6.8 - - His124, Phe125, Ala128, Pro131, 
Arg134, Gln170, Tyr171
FIGURE 2. Chemical structure of the top ten compounds and L-38. The pyridine group (blue box) consists of Q-96, Q-93, Q-82, 
Q-83, Q-88 and Q-100 that have two benzene rings, triazole and pyridine except for Q-83 which has an oxadiazole ring instead of 
triazole. The piperidine group (orange box) consists of Q-94, Q-97, Q-98 and Q-99 with chemical structure containing benzene, 
oxadiazole, piperidine and carboxamide rings. L-38 has similar scaffold of chemical structure to the pyridine group
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et al. 2001), poor absorption and lower solubility (Lipinski 
et al. 1997) while low lipophilicity compounds generally 
have poor ADMET properties (Arnott & Planey 2012).
Meanwhile, water-solubility properties prediction 
based on ESOL model through the Log S calculation 
showed that all compounds exhibited moderate solubility 
(Table 4). This is understood as all the compounds have 
molecular weight more than 400 g/mol and lipophilicity 
(log P) in the range of 2.2 to 3.4 as an increase in molecular 
weight and lipophilicity will decrease the water solubility. 
However, having poorly soluble compounds in designing 
drug is not a major problem as several strategies have been 
employed to overcome this problem (Lipinski 2002). This 
includes the use of complexing drugs with cyclodextrins 
(Vyas et al. 2008), ionized drug through salt formation 
(Serajuddin 2007), conjugation to dendrimers (Gupta et 
al. 2006) and the use of co-solvents (Akers 2002; Strickley 
2004). 
As tabulated in Table 4, some of the compounds have 
high GI absorption prediction (Q-96, Q-82, Q-97, Q-94, 
Q-98 and Q-99) while some have low GI absorption 
prediction (Q-83, Q-93, Q-88, Q-100 and L-38). GI 
absorption is an important parameter in the drug delivery 
process. Poor GI absorption will have caused low drug 
level absorbed from the gut into the bloodstream thus will 
affect the overall oral bioavailability (Clark 2011). 
Interestingly all ligands did not have PAINS (Baell & 
Holloway 2010) or Brenk (Brenk et al. 2008) alerts 
indicates that all ligands do not have any unfavourable 
moieties or fragments in their chemical structure. 
CONCLUSION
We have used computational approaches to screen potential 
compounds that can be targeted against Ebola VP40-RNA 
binding site. In this work, we found several compounds 
with good binding energy at the RNA binding site with 
satisfying ADME properties. Q-96 (ZINC ID: 1338855) 
is the best binding ligand with no major ADME problem. 
Other ligands namely Q-82, Q-97, Q-94 and Q-98 could 
also serve as potential inhibitors to inhibit VP40-RNA 
activity. This study produces a set of potential compounds, 
in which its inhibitory activity can be further validated via 
an experimental approach such as enzymatic assay. A more 
TABLE 3. Drug likeness violations and bioavailability score for each ligand. (MW= Molecular weight, MR= Molar refractivity, 
TPSA= Topological polar surface area)




Q-96 0 0 0 0 0 0.55
Q-82 0 0 0 0 0 0.55
Q-97 0 0 0 0 0 0.55
Q-83 0 0 0 1(TPSA>131.6) 0 0.55
Q-93 0 0 0 0 0 0.55
Q-88 0 2 (MW>480, MR>130) 0 0 0 0.55
Q-94 0 0 0 0 0 0.55
Q-98 0 0 0 0 0 0.55
Q-99 0 1 (MR>130) 0 0 0 0.55
Q-100 0 1 0 0 0 0.55
TABLE 4. ADME properties for each ligand
Ligands ZINC ID Consensus Log P ESOL Log S ESOL Class GI absorption PAINS alerts Brenk alerts
Q-96 1338855 2.99 -4.48 Moderately soluble High 0 0
Q-82 1338833 2.93 -4.48 Moderately soluble High 0 0
Q-97 40958549 3.04 -5.47 Moderately soluble High 0 0
Q-83 59213111 3.16 -4.61 Moderately soluble Low 0 0
Q-93 1338837 2.85 -4.33 Moderately soluble Low 0 0
Q-88 1342431 3.39 -4.96 Moderately soluble Low 0 0
Q-94 40930748 2.98 -5.29 Moderately soluble High 0 0
Q-98 41279804 2.44 -4.52 Moderately soluble High 0 0
Q-99 41279972 2.23 -4.4 Moderately soluble High 0 0
Q-100 1342435 3.28 -4.67 Moderately soluble Low 0 0
L-38 - 3.11 -4.77 Moderately soluble Low 0 0
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detail analysis at the molecular level on the protein-ligand 
interaction such as molecular dynamics simulation should 
be done on the potential compounds to monitor the stability 
of the VP40-ligand complexes. Besides, more accurate 
binding energy calculation like MM-PBSA can be carried 
out to further justify the ligands-protein interaction and 
give more insights on the suitable chemical scaffold that 
suit the RNA binding site.
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